首页 | 本学科首页   官方微博 | 高级检索  
     


Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma
Authors:Daniel J. Lee  Evanguelos Xylinas  Malte Rieken  Francesca Khani  Tobias Klatte  Christopher G. Wood  Jose A. Karam  Alon Z. Weizer  Jay D. Raman  Mesut Remzi  Charles C. Guo  Nathalie Rioux-Leclercq  Andrea Haitel  Christian Bolenz  Karim Bensalah  Arthur I. Sagalowsky  Francesco Montorsi  Yair Lotan  Shahrokh F. Shariat  Brian D. Robinson  Vitaly Margulis
Affiliation:1. Department of Urology, Weill Cornell Medical College, New York, NY, USA;2. Inserm U955 Equipe 07, UPEC, Créteil, France;3. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France;4. Department of Urology, University Hospital Basel, Basel, Switzerland;5. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA;6. Department of Urology, Medical University of Vienna, Vienna, Austria;g Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;h Department of Urology, University of Michigan, Ann Arbor, MI, USA;i Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA;j Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;k Department of Pathology, University of Rennes, Rennes, France;l Department of Pathology, Medical University of Vienna, Vienna, Austria;m Department of Urology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany;n Department of Urology, University of Rennes, Rennes, France;o Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA;p Department of Urology, Vita-Salute University, Milan, Italy
Abstract:

Background

Upper tract urothelial carcinoma (UTUC) is a clinically heterogeneous disease that lacks high-quality trials that provide definitive prognostic markers. Insulin-like growth factor messenger RNA binding protein 3 (IMP3) has been associated with outcomes in urothelial carcinoma of the bladder but was not yet studied in UTUC.

Objective

To evaluate the association of the oncofetal protein IMP3 with oncologic outcomes in patients with UTUC treated with radical nephroureterectomy (RNU).

Design, setting, and participants

We investigated the expression of IMP3 and its association with clinical outcomes using tissue microarrays constructed from 622 patients treated with RNU at seven international institutions between 1991 and 2008.

Intervention

All patients were diagnosed with UTUC and underwent RNU.

Outcome measurement and statistical analysis

Uni- and multivariable Cox regression analyses evaluated the association of IMP3 protein expression with disease recurrence, cancer-specific mortality, and all-cause mortality.

Results and limitations

IMP3 was expressed in 12.2% of patients with UTUC (n = 76). The expression was tumor specific and correlated with higher stages/grades. Within a median follow-up of 27 mo (interquartile range [IQR]: 12–53), 191 patients (25.4%) experienced disease recurrence, and 165 (21.9%) died of the disease. Patients with IMP3 demonstrated significantly worse recurrence-free survival (27.4% vs 75.1%; p < 0.01), cancer-specific survival (34.5% vs 78.9%; p < 0.01), and overall survival (15.6% vs 64.8%; p < 0.01) at 5 yr compared with those without IMP3. In multivariable Cox regression analyses, which adjusted for the effects of standard clinicopathologic features, IMP3expression was independently associated with disease recurrence (hazard ratio [HR]: 1.87; p < 0.01), cancer-specific mortality (HR: 2.15; p < 0.01), and all-cause mortality (HR: 2.07; p < 0.01). Major limitations include the retrospective design and relatively short follow-up time.

Conclusions

IMP3 expression is independently associated with disease recurrence, cancer-specific mortality, and all-cause mortality in UTUC. IMP3 may help improve risk stratification and prognostication of UTUC patients treated with RNU.
Keywords:IMP-3   Immunohistochemistry   Upper tract urothelial carcinoma   Biomarker   Outcomes   Prognosis   Disease recurrence   Survival
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号